Altre lingue Palatin Technologies, Inc.

Azioni

PTN

US6960775020

Tempo reale stimato Cboe BZX Altri mercati azionari 16:18:31 03/07/2024			Variaz. 5gg	Var. 1 gen.
1,895 ^USD	+0,80%		+2,20%	-53,27%

20/06	Palatin Technologies, Inc. annuncia l'inizio di uno studio clinico di Fase 2 di Bremelanotide co-somministrato con PDE5i per il trattamento della disfunzione erettile	CI
12/06	Aggiornamento settoriale: i titoli del settore sanitario calano nel tardo pomeriggio	MT

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

Palatin Technologies, Inc.(NYSEAM:PTN) added to Russell 3000E Value Index	01/07
Palatin Announces Exercise of Warrants for Approximately $6.1 Million Gross Proceeds	24/06
Palatin Announces the Initiation of a Phase 2 Clinical Study of Bremelanotide Co-Administered with a PDE5i for the Treatment of Erectile Dysfunction	21/06
Palatin Technologies, Inc. Announces Initiation of Phase 2 Clinical Study of Bremelanotide Co-Administered with PDE5i for Treatment of Erectile Dysfunction	20/06
Palatin Initiates Phase 2 Clinical Study of Bremelanotide for the Treatment of Obesity	13/06
Sector Update: Health Care Stocks Ease Late Afternoon	12/06
Palatin Technologies Starts Phase 2 of Obesity Treatment Study	12/06
Palatin Technologies, Inc. Initiates Phase 2 Clinical Study of Bremelanotide for the Treatment of Obesity	12/06
Palatin Reports Third Quarter Fiscal Year 2024 Financial Results and Provides Corporate Update	16/05
Palatin Technologies, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2024	15/05
Palatin to Report Third Quarter Fiscal Year 2024 Results, Teleconference and Webcast to be held on May 15, 2024	10/05
Palatin Announces FDA Clearance of IND Application for the Co-Administration of Bremelanotide with Tirzepatide for the Treatment of Obesity	03/05
Palatin to Host Virtual KOL Event 'Beyond GLPs, the Multiple Roles for Novel Melanocortin Receptor 4 Agonists in Treating Obesity and Weight Loss Maintenance' on May 8, 2024	01/05
PALATIN ANNOUNCES PHASE 3 PL9643 MELODY-1 DRY EYE DISEASE CLINICAL DATA RESULTS PRESENTED AT AMERICAN SOCIETY OF CATARACT AND REFRACTIVE SURGERY 2024	09/04
Palatin Announces Phase 3 Pl9643 Melody-1 Dry Eye Disease Clinical Data Results Presented At American Society of Cataract and Refractive Surgery 2024	08/04
PALATIN ANNOUNCES RESULTS OF PL9643 MELODY-1 PIVOTAL PHASE 3 CLINICAL TRIAL IN PATIENTS WITH DRY EYE DISEASE	29/02
Sector Update: Health Care Stocks Decline Late Afternoon	28/02
Palatin Shares Skid After Dry Eye Drug Candidate Misses Part of Targets in Late-Stage Trial	28/02
Palatin Technologies, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2023	14/02
PALATIN ANNOUNCES DATABASE LOCK FOR PL9643 MELODY-1 PIVOTAL PHASE 3 CLINICAL TRIAL IN PATIENTS WITH DRY EYE DISEASE	06/02

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Palatin Technologies, Inc.

Azioni

PTN

US6960775020

Altre lingue

Filtri